Streetbeat News

Stock Prices

CMPX

Compass Therapeutics (NASDAQ:CMPX) has completed patient enrollment for its COMPANION-002 Phase 2/3 trial of CTX-009 in combination with paclitaxel for biliary tract cancer. The company also approved an Investigator Sponsored Trial (IST) of CTX-009 in the first-line setting for BTC patients.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:14 pm

RMCF

Rocky Mountain Chocolate Factory Inc. (NASDAQ:RMCF) announced a $2.2 million private placement of 1.25 million shares at $1.75 per share, a 15% premium to the closing stock price on August 5, 2024. The proceeds will be used for working capital and general corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:13 pm

SPY

Jim Cramer suggests that a Trump presidency could be beneficial for income earners and investors, citing potential tax cuts. However, there are concerns about increased tariffs, inflation, and higher mortgage rates. The SPDR S&P 500 ETF Trust (SPY) rose 0.90% despite recent sell-offs.

Portfolio Pulse from Shanthi Rexaline

August 06, 2024 | 12:13 pm

TARA

Protara Therapeutics (NASDAQ:TARA) reported a Q2 EPS of $(0.45), beating the analyst estimate of $(0.80) by 43.75%. This represents a 55% improvement over the $(1.00) loss per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:13 pm

RXST

RxSight Inc (NASDAQ:RXST) reported strong Q2 sales, beating analyst estimates and raising its FY24 revenue forecast. Despite this, shares fell 2.4% as analysts lowered their price targets.

Portfolio Pulse from Avi Kapoor

August 06, 2024 | 12:12 pm

DAVE

Dave shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 revenue guidance.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:12 pm

EQ

Equillium, Inc. announced a positive recommendation from the Independent Data Monitoring Committee (IDMC) for its Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD). The IDMC recommended the continuation of the trial based on safety and efficacy assessments. This triggers a 90-day period for Ono Pharmaceutical Co., Ltd. to exercise its option to acquire Equillium's rights to itolizumab for JPY 5 billion plus potential milestone payments.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:12 pm

FXI

TSLA

Tesla is recalling 1,683,627 cars in China, as reported by Bloomberg citing CCTV.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:12 pm

SOLUSD

TrumpCoin, a meme coin based on Solana, experienced a dramatic 98% drop in value. Despite the crash, trading volume surged significantly. The coin gained attention due to claims of involvement by Martin Shkreli and Barron Trump, which were later denied by Roger Stone. The volatility of TrumpCoin underscores the unpredictable nature of the crypto market.

Portfolio Pulse from Murtuza Merchant

August 06, 2024 | 12:09 pm

VTAK

Catheter Precision, Inc. (NYSE:VTAK) announced the publication of its first LockeT study in the Journal of Cardiovascular Electrophysiology. The study demonstrates the effectiveness and safety of the LockeT device in achieving hemostasis and facilitating early ambulation without major complications. Further studies are planned for this year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:08 pm